{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:21:27Z","timestamp":1785543687063,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1053\/j.seminoncol.2022.01.006","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:17:21Z","timestamp":1643609841000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions"],"prefix":"10.1053","volume":"49","author":[{"given":"Monika","family":"Chojnacka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-20-1395","article-title":"Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma","volume":"27","author":"Maura","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.006_bib0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminoncol.2022.01.006_bib0003","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (Asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.006_bib0004","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.006_bib0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.006_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.006_bib0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.006_bib0008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.0954-6820.1984.tb05032.x","article-title":"Benign monoclonal gammapathy","volume":"216","author":"Waldenstrom","year":"1984","journal-title":"Acta Med Scand"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.006_bib0009","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"24","key":"10.1053\/j.seminoncol.2022.01.006_bib0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.006_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamaoncol.2019.4659","article-title":"Moving From cancer burden to cancer genomics for smoldering myeloma: a review","volume":"6","author":"Maura","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.006_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1053\/j.seminoncol.2022.01.006_bib0014","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-07-0031","article-title":"Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients","volume":"13","author":"Brousseau","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.006_bib0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.006_bib0017","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2022.01.006_bib0019","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0020","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.006_bib0021","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0022","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.006_bib0023","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41375-021-01130-7","article-title":"Positive selection as the unifying force for clonal evolution in multiple myeloma","volume":"35","author":"Diamond","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.006_bib0024","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.006_bib0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.006_bib0026","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-16-2810","article-title":"Mutational signatures in breast cancer: the problem at the DNA level","volume":"23","author":"Nik-Zainal","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0027","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0028","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.006_bib0029","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminoncol.2022.01.006_bib0031","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.006_bib0032","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"issue":"7793","key":"10.1053\/j.seminoncol.2022.01.006_bib0033","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"7463","key":"10.1053\/j.seminoncol.2022.01.006_bib0034","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.006_bib0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0036","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1038\/s41467-019-11037-8","article-title":"A practical guide for mutational signature analysis in hematological malignancies","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0037","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1053\/j.seminoncol.2022.01.006_bib0038","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.006_bib0039","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","article-title":"The mutagenic impact of melphalan in multiple myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.006_bib0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1101\/gr.230219.117","article-title":"In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors","volume":"28","author":"Boot","year":"2018","journal-title":"Genome Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.006_bib0041","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","article-title":"The mutational footprints of cancer therapies","volume":"51","author":"Pich","year":"2019","journal-title":"Nat Genet"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.006_bib0042","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.006_bib0043","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","article-title":"APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity","volume":"5","author":"Swanton","year":"2015","journal-title":"Cancer Discov"},{"issue":"7779","key":"10.1053\/j.seminoncol.2022.01.006_bib0044","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","article-title":"The landscape of somatic mutation in normal colorectal epithelial cells","volume":"574","author":"Lee-Six","year":"2019","journal-title":"Nature"},{"issue":"7793","key":"10.1053\/j.seminoncol.2022.01.006_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","article-title":"Patterns of somatic structural variation in human cancer genomes","volume":"578","author":"Li","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.006_bib0046","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ng.3771","article-title":"A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers","volume":"49","author":"Glodzik","year":"2017","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2022.01.006_bib0047","article-title":"Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups","author":"Boyle","year":"2021","journal-title":"Leukemia"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:57:32Z","timestamp":1758805052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775422000069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0093775422000069"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}